Skip to Content

Invokamet Dosage

Generic name: canagliflozin 50mg, metformin hydrochloride 500mg
Dosage form: tablet, film coated

See also:

Medically reviewed by Drugs.com. Last updated on Aug 21, 2020.

Prior to Initiation of INVOKAMET/INVOKAMET XR

Dosage Overview

  • INVOKAMET dosing is one tablet, twice daily with meals.
  • INVOKAMET XR dosing is two tablets, once daily with the morning meal. Swallow each tablet whole and never crush, cut, or chew.
  • The starting and maintenance dose of INVOKAMET/INVOKAMET XR is based on the patient's current regimen and renal function [see Dosage and Administration (2.3, 2.4)].
  • The maximum recommended daily dose is canagliflozin 300 mg and metformin HCl 2,000 mg in patients with an estimated glomerular filtration rate (eGFR) of 60 mL/min/1.73 m2 or greater. The recommended dosage for patients with renal impairment is shown in Table 1 [see Dosage and Administration (2.4)].

Starting Dose Based on Patient's Current Regimen

Individualize the starting dose of INVOKAMET/INVOKAMET XR based on the patient's current regimen and renal function [see Dosage and Administration (2.4)]:

Patients Currently not Treated with Either Canagliflozin or Metformin HCl

  • INVOKAMET: One tablet, twice daily, each tablet containing canagliflozin 50 mg and metformin HCl 500 mg;
  • INVOKAMET XR: Two tablets, once daily, each tablet containing canagliflozin 50 mg and metformin HCl 500 mg.

Patients on Metformin HCl

  • INVOKAMET: One tablet, twice daily, where the total daily dose contains canagliflozin 100 mg and the same, or nearest appropriate, daily dose of metformin HCl;
  • INVOKAMET XR: Two tablets, once daily, where the total daily dose contains canagliflozin 100 mg and the patient's same, or nearest appropriate, daily dose of metformin HCl.

Patients on Canagliflozin

  • INVOKAMET: One tablet, twice daily, where the total daily dose contains the same daily dose of canagliflozin and metformin HCl 1,000 mg;
  • INVOKAMET XR: Two tablets, once daily, where the total daily dose contains the patient's same daily dose of canagliflozin and metformin HCl 1,000 mg.

Patients Already Treated with Canagliflozin and Metformin HCl

  • INVOKAMET: One tablet, twice daily, where the total daily dose contains the same daily dose of canagliflozin and the same, or nearest appropriate, daily dose of metformin HCl;
  • INVOKAMET XR: Two tablets, once daily, where the total daily dose contains the same daily dose of canagliflozin and the same, or nearest appropriate, daily dose of metformin HCl.

Patients with eGFR of 60 mL/min/1.73 m2 or Greater and Require Additional Glycemic Control

  • INVOKAMET: For patients tolerating canagliflozin 50 mg twice daily, increase the dose of canagliflozin to 150 mg twice daily, with gradual metformin HCl dose escalation based on tolerability [see Adverse Reactions (6.1)];
  • INVOKAMET XR: For patients tolerating a daily dose of canagliflozin 100 mg, increase the dose to 300 mg once daily, with gradual metformin HCl dose escalation based on tolerability [see Adverse Reactions (6.1)].

Patients on Evening Dose of Metformin HCl Extended-Release Tablets

Patients taking an evening dose of metformin HCl extended-release tablets should skip their last dose before starting INVOKAMET/INVOKAMET XR the following morning.

Recommended Dosage for Patients with Renal Impairment

Table 1: Recommended Dosage
estimated Glomerular Filtration Rate
eGFR (mL/min/1.73 m2)
Recommended Dosage
eGFR 60 or greater [See Dosage and Administration (2.3)].
eGFR 45 to less than 60 Limit the dose of canagliflozin component to 100 mg daily (two 50 mg tablets).
eGFR 30 to less than 45 Assess the benefit risk of continuing INVOKAMET or INVOKAMET XR; limit the dose of canagliflozin component to 100 mg daily (two 50 mg tablets).
eGFR less than 30 Contraindicated; discontinue INVOKAMET or INVOKAMET XR [see Contraindications (4)].
On dialysis Contraindicated [see Contraindications (4)].

Concomitant Use with UDP-Glucuronosyltransferase Enzyme Inducers

Patients with eGFR 60 mL/min/1.73 m2 or greater

If an inducer of UDP-Glucuronosyltransferase (UGT) (e.g., rifampin, phenytoin, phenobarbital, ritonavir) is co-administered with INVOKAMET/INVOKAMET XR, increase the total daily dose of canagliflozin to 200 mg in patients currently tolerating a total daily dose of canagliflozin 100 mg. The total daily dose of canagliflozin may be increased to a maximum of 300 mg in patients currently tolerating canagliflozin 200 mg and who require additional glycemic control [see Drug Interactions (7.2)].

Patients with eGFR less than 60 mL/min/1.73 m2

If an inducer of UGTs (e.g., rifampin, phenytoin, phenobarbital, ritonavir) is co-administered with INVOKAMET/INVOKAMET XR, increase the total daily dose of canagliflozin to a maximum of 200 mg in patients currently tolerating canagliflozin 100 mg.

Discontinuation for Iodinated Contrast Imaging Procedures

Discontinue INVOKAMET/INVOKAMET XR at the time of, or prior to, an iodinated contrast imaging procedure in patients with an eGFR of less than 60 mL/min/1.73 m2; in patients with a history of liver disease, alcoholism or heart failure; or in patients who will be administered intra-arterial iodinated contrast. Re-evaluate eGFR 48 hours after the imaging procedure; restart INVOKAMET/INVOKAMET XR if renal function is stable [see Warnings and Precautions (5.1)].

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.